Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Natural CapsulesBOM:524654 +3.42%43 EBITDA Margin % is 3.58% as of Mar. 2026, which is 69% below its 10-year median of 11.50. GuruFocus rates BOM:524654 with a GF Score™ of 43/100 and a GF Value™ of ₹313.68 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, Natural Capsules ranks worse than 74.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Natural Capsules's EBITDA for the
three
months ended in Mar. 2026 was ₹21 Mil. Natural Capsules's Revenue for the
three
months ended in Mar. 2026 was ₹585 Mil. Therefore, Natural Capsules's EBITDA margin for the quarter that ended in Mar. 2026 was 3.58%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Natural Capsules EBITDA Margin % Related Terms
Natural Capsules EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Natural Capsules's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Natural Capsules's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natural Capsules EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natural Capsules's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Natural Capsules's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natural Capsules (BOM:524654) has a EBITDA Margin % of 3.58% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Natural Capsules and its competitors. This is 69% below median its historical median of 11.50. Over the past decade, Natural Capsules' EBITDA Margin % has ranged from 0.09 to 21.62. According to the industry distribution chart, Natural Capsules ranks #718 out of 959 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Natural Capsules' EBITDA Margin % too high?
Natural Capsules' current EBITDA Margin % of 3.58% is 69% below median its 10-year median of 11.50. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 21.62. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Natural Capsules' value of 3.58% is 70.4% below this industry median. Based on the distribution chart, Natural Capsules ranks #718 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Natural Capsules has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Natural Capsules' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Natural Capsules ranks #718 out of 959 companies for EBITDA Margin %. This places Natural Capsules in the lower half of its industry. The industry median EBITDA Margin % is 12.11. Natural Capsules' value of 3.58% is 70.4% below this benchmark. Historically, Natural Capsules' own EBITDA Margin % has ranged from 0.09 to 21.62 over the past decade. While the company's 10-year median is 11.50 vs. the industry median of 12.11, Natural Capsules has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natural Capsules's current EBITDA Margin % of 3.58% is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Natural Capsules and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natural Capsules's current EBITDA Margin % is 3.58%, which is 69% below median its own 10-year median of 11.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natural Capsules stock overvalued right now?
Based on GuruFocus' analysis, Natural Capsules (BOM:524654) is currently considered Possible Value Trap. The stock's GF Value™ is ₹313.68, compared to a current price of ₹155.80 — trading 50.3% below its estimated fair value. The current EBITDA Margin % is 3.58%, which is 69% below median its 10-year median of 11.50 and 70.4% below the Drug Manufacturers industry median of 12.11. Natural Capsules' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Natural Capsules (BOM:524654), the current EBITDA Margin % is 3.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natural Capsules (BOM:524654) Overvalued in 2026?
Based on GuruFocus' analysis, Natural Capsules stock appears to be undervalued.
The current stock price of ₹155.80 is trading 50.3% below its estimated GF Value™ of ₹313.68.
GuruFocus considers Natural Capsules to be Possible Value Trap.
Key valuation signals for BOM:524654:
EBITDA Margin %: 3.58% (69% below median its 10-year median of 11.50)
GF Value™: ₹313.68 vs. price of ₹155.80 (50.3% below fair value)
Industry Position: 70.4% below the Drug Manufacturers median (#718 of 959)
No single metric tells the full story. See the BOM:524654 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natural Capsules Ltd is an India-based company engaged in the manufacturing and selling of empty hard gelatin capsules. The products of the company are Hard gelatin capsule shells, Hard cellulose capsule shells, Shiny gelatin capsule shells, Sweet gelatin capsule shells, Enteric capsule shells, Printed gelatin capsule shells, Vegetarian capsule shells, Fortified gelatin capsule shells, and other capsules. It is also involved in formulating pharmaceutical dosage forms in capsule dosage form, both pharma and nutraceutical products.
43GF Score
Get the complete analysis for BOM:524654
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524654 has been successfully added to your 
